Qrons (QRON) Common Stock: $0.00 Mil (As of Dec. 2024)


What is Qrons Common Stock?

Qrons QRON Common Stock is $0.00 Mil as of Dec. 2024.

Qrons's quarterly common stock stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then increased from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Qrons's annual common stock stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Qrons Common Stock Historical Data

* Premium members only.

The historical data trend for Qrons's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qrons Common Stock Chart

Qrons Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Qrons Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Qrons Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.00 Mil mean?
Qrons (QRON) has a Common Stock of $0.00 Mil as of Dec. 2024. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Qrons and its competitors.
Is Qrons' Common Stock too high?
Qrons' current Common Stock is $0.00 Mil.
How does Qrons' Common Stock compare to GBLX and ENDV?
Qrons' Common Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Qrons and its competitors. Qrons's current Common Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qrons stock overvalued right now?
Qrons (QRON) has a current Common Stock of $0.00 Mil. The current Common Stock is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Qrons (QRON), the current Common Stock is $0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Qrons Business Description

Address 611 N. Brand Boulevard, Suite 1300, Glendale, CA, USA, 91203
Qrons Inc. is a biotechnology company, dedicated to developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic-resistant bacteria, which is becoming the prominent and rapidly growing world-wide cause of illness and death. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The company has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM for treating concussions and other diffused axonal injuries.